are there any natural glp-1 agonists receptor and next-generation metabolic hormone therapies in chronic kidney disease What Is GLP-1 and Why

Description

Advertisement SELECT was designed to determine whether semaglutide can exert protective cardiovascular effects in patients with overweight or obesity in the absence of diabetes

In case youre wondering, the price of safety was rather reasonable

Disclosures Jos Luis Grriz has served as consultant to Boehringer Ingelheim, Mundipharma, AstraZeneca, and Novo Nordisk and has received speaker honoraria from Boehringer Ingelheim, Mundipharma, AstraZeneca, Novo Nordisk, Novartis, and Eli Lilly and Company

HarrisonSAFriasJPLucasKJReissGNeffGBollepalliSet al

Future research objectives must concentrate on creating prediction algorithms for appropriate receptor targeting ratios, exploring triple-agonist strategies (GLP-1/GIP/glucagon), and determining long-term safety profiles for multi-receptor therapies